Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
申请人:Pauls Heinz W.
公开号:US08765748B2
公开(公告)日:2014-07-01
The present invention is directed to a compound is represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.
[EN] SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1,3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS<br/>[FR] HÉTÉROCYCLYL-1,3-DIHYDRO-INDOL-2-ONES INSATURÉES ET SUBSTITUÉES À 3-5 ÉLÉMENTS ET LEURS DÉRIVÉS EN TANT QU'INHIBITEURS DE KINASE
申请人:ALLERGAN INC
公开号:WO2007087419A2
公开(公告)日:2007-08-02
[EN] The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. [FR] Molécules organiques capables de moduler la transduction du signal de la tyrosine kinase afin de réguler, moduler et / ou inhiber la prolifération cellulaire anormale.